Literature DB >> 30725297

Biosimilars in IBD: Similarity Breeds Contented Patients.

Vito Annese1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30725297     DOI： 10.1007/s10620-019-05499-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

Review 1.  American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.

Authors:  Niels Vande Casteele; Hans Herfarth; Jeffry Katz; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-07-31       Impact factor: 22.682

Review 2.  Biologic agents for IBD: practical insights.

Authors:  Silvio Danese; Lucine Vuitton; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-08-18       Impact factor: 46.802

3.  Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.

Authors:  Antoine Meyer; Jérémie Rudant; Jérôme Drouin; Alain Weill; Franck Carbonnel; Joël Coste
Journal:  Ann Intern Med       Date:  2018-12-11       Impact factor: 25.391

4.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

Review 5.  The challenge of indication extrapolation for infliximab biosimilars.

Authors:  Brian G Feagan; Denis Choquette; Subrata Ghosh; Dafna D Gladman; Vincent Ho; Bernd Meibohm; Guangyong Zou; Zhenhua Xu; Gopi Shankar; David C Sealey; Anthony S Russell
Journal:  Biologicals       Date:  2014-06-21       Impact factor: 1.856

6.  Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.

Authors:  Georgios Bakalos; Elias Zintzaras
Journal:  Clin Ther       Date:  2018-12-11       Impact factor: 3.393

Review 7.  Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO.

Authors:  Vito Annese; Dana Duricova; Corinne Gower-Rousseau; Tine Jess; Ebbe Langholz
Journal:  J Crohns Colitis       Date:  2015-10-31       Impact factor: 9.071

8.  Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.

Authors:  Nikolas Plevris; Gareth R Jones; Philip W Jenkinson; Mathew Lyons; Cher S Chuah; Lynne M Merchant; Rebecca J Pattenden; Eleanor F Watson; Gwo-Tzer Ho; Colin L Noble; Shahida Din; Alan G Shand; Ian D Arnott; Charlie W Lees
Journal:  Dig Dis Sci       Date:  2018-12-07       Impact factor: 3.487

Review 9.  Insights on the use of biosimilars in the treatment of inflammatory bowel disease.

Authors:  Michael K Zheng; David Q Shih; Gary C Chen
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.